ONESOURCEOnesource Specialty Pharma Limited
Convert to ideaPharmaceuticals & Biotechnology · Pharmaceuticals · India Ratings: A (Positive)
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeDown 0.6 this quarter.
Momentum from moving averages, Supertrend and RSI.
6 forensic issues found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
6 found · risk severe
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹516 Cr | ₹57 Cr | 17.09% | 11.14% | ₹5.01 | 2.5x |
| Q1 FY2027 | ₹449 Cr | ₹25 Cr | 11.49% | 5.57% | ₹2.18 | 1.7x |
| Q4 FY2026 | ₹428 Cr | ₹5 Cr | 4.69% | 1.07% | ₹0.40 | 1.0x |
| Q3 FY2026 | ₹290 Cr | ₹-89 Cr | -18.02% | -30.55% | ₹-7.74 | -1.4x |
| Q2 FY2026 | ₹376 Cr | ₹10 Cr | 9.76% | 2.79% | ₹0.92 | 1.2x |
| Q1 FY2026 | ₹327 Cr | ₹-0 Cr | 6.32% | -0.06% | ₹-0.02 | 0.8x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.